BioCatalyst

AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID — catalyst calendar

1 verified catalyst event(s) referencing AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID, each linked to its official source. Verified as of 2026-10-27.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-02-28
in 4mo
ESTIMATED
 READOUT
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in
Phase 2 · Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
 R1 Therapeutics AP306 75 mg BID, AP306 125 mg BID, AP306 ClinicalTrials.gov ↗
✓ Source-checked 2026-10-27
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.